The U.S. government exercised an option for an additional 100 million doses of the Pfizer-BioNTech Covid-19 vaccine, bringing the total number of doses to be supplied by the companies to the United States to 300 million.
Bristol Myers Squibb reported that the company was abandoning the BCMA CAR-T therapy orva-cel and taking a $470 million write-off.
Amanda Powers-Han, Senior Partner and Chief Marketing Officer for Greater Than One, explores some real-life technology applications that are transforming healthcare today and tomorrow.
Switzerland-based AC Immune SA announced positive interim results from the company’s ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.
The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court.
Merck & Co. Inc. was in talks with governments and companies to potentially help with manufacturing of Covid-19 vaccines that have been already authorized.
AstraZeneca expects to produce more than 100 million doses of the company’s Covid-19 vaccine – developed with Oxford University – during February, ramping up to more than 200 million a month by April, Chief Executive Pascal Soriot said.
AbbVie announced the company’s latest chimeric antigen receptor (CAR)-T cell investment, a collaboration with Caribou Biosciences worth $40 million up front in cash and equity to develop two CRISPR-edited cell therapies against AbbVie-specified targets.
Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.
The program unites academia and industry, providing students with a real-world, skills-based education and direct connections to leaders in healthcare marketing and communications.
